CRBU (Caribou Biosciences) Research & Development: $94.52 Mil (TTM As of Mar. 2026)


CRBU Caribou Biosciences Inc CRBU
66 GF Score
Price $1.67
GF Value $1.70
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Caribou Biosciences Research & Development?

Caribou Biosciences CRBU +7.01% 66 Research & Development is $94.52 Mil as of Mar. 2026. GuruFocus rates CRBU with a GF Score™ of 66/100 and a GF Value™ of $1.70 (Fairly Valued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Caribou Biosciences's Research & Development for the three months ended in Mar. 2026 was $20.61 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $94.52 Mil.

Caribou Biosciences  (NAS:CRBU) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Caribou Biosciences Research & Development Related Terms

Caribou Biosciences Research & Development Historical Data

* Premium members only.

The historical data trend for Caribou Biosciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caribou Biosciences Research & Development Chart

Caribou Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 52.26 82.23 112.08 130.15 109.44

Caribou Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.53 27.69 22.40 23.82 20.61
CRBU
66GF Score
Caribou Biosciences Inc CRBU
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caribou Biosciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $94.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $94.52 Mil mean?
Caribou Biosciences (CRBU) has a Research & Development of $94.52 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Caribou Biosciences and its competitors.
Is Caribou Biosciences' Research & Development too high?
Caribou Biosciences' current Research & Development is $94.52 Mil. Overall, Caribou Biosciences has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Caribou Biosciences' Research & Development compare to YDES and PRQR?
Caribou Biosciences' Research & Development of $94.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Caribou Biosciences and its competitors. Caribou Biosciences's current Research & Development is $94.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caribou Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Caribou Biosciences (CRBU) is currently considered Fairly Valued. The stock's GF Value™ is $1.70, compared to a current price of $1.67 — trading 1.8% below its estimated fair value. The current Research & Development is $94.52 Mil. Caribou Biosciences' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Caribou Biosciences (CRBU), the current Research & Development is $94.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caribou Biosciences (CRBU) Overvalued in 2026?

Based on GuruFocus' analysis, Caribou Biosciences stock appears to be undervalued. The current stock price of $1.67 is trading 1.8% below its estimated GF Value™ of $1.70. GuruFocus considers Caribou Biosciences to be Fairly Valued.

Key valuation signals for CRBU:

  • Research & Development: $94.52 Mil
  • GF Value™: $1.70 vs. price of $1.67 (1.8% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Caribou Biosciences Business Description

Address 2929 7th Street, Suite 105, Berkeley, CA, USA, 94710
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
66GF Score

Get the complete analysis for CRBU

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.67
Price
$1.70
GF Value